Pharmacy Technology & Delivery

22 confirmed failures

Funding Burned

$636.9M

Median Lifespan

7 years

Dominant Failure

Competitive Displacement

27% of cases

Period

2009 — 2024

Failure Pattern Distribution

Outspent by bigger competitors6 (27%)

Couldn't prove the product worked4 (18%)

Customer acquisition costs too high2 (9%)

Couldn't get paid by insurance2 (9%)

Couldn't connect to existing systems2 (9%)

Ran out of money before clinical trials2 (9%)

Preclinical science did not translate2 (9%)

Regulation moved faster than the company1 (5%)

Multi-stakeholder approval bottleneck1 (5%)

Curator's Note

auto-generated

This section of the registry contains 22 healthcare Pharmacy Technology & Delivery startups that shut down between 2009 and 2024, representing $636.9M in combined funding. The dominant failure pattern is Competitive Displacement (27% of cases). Clinical Validation Gap accounts for another 18%. These entries were coded using the Gioia three-level qualitative methodology. Inter-rater reliability: 0.82 (strong agreement). This note is auto-generated and will be replaced by editorial analysis.

Have a correction? Reach out.

Sample verdict

pre-rendered

Based on 25 Pharmacy Technology & Delivery failures in the corpus. Not your thesis.

KILLEDKill threshold 61%

Couldn't prove the product worked

Buyers need proof your product works, and you do not have it yet.

Precedents

Alto Pharmacy (HC-0053) · 2023
Truepill (HC-0055) · 2024
Axial Healthcare (HC-0131) · 2019

Run this against your thesis →

Cost of Inaction

Cost of Inaction — Workflow Cost

Your workflow area

Hours/week spent on this workflow

Cost of Inaction — Startup Risk

Your vertical

Funding stage

Target runway (months)

Building in pharmacy technology & delivery? Stress-test your thesis against these 22 failures.